A CAR-engineered NK cell targeting both WT EGFR and EGFRvIII mutant, NK-92-EGFR-CAR, was similarly efficient in targeting and killing GBM cells in mice engrafted with patients' mesenchymal GBM stem cells (85). The gene discussed is EGFR; the disease is glioblastoma.